Crinetics Pharmaceuticals Inc
CRNX27.875USD
+0.035+0.13%
交易中 （美东）报价延迟15分钟
2.61B总市值
亏损市盈率 TTM
关于 Crinetics Pharmaceuticals Inc 公司
Crinetics Pharmaceuticals, Inc. 是一家临床阶段制药公司，专注于发现、开发和商业化罕见内分泌疾病和内分泌相关肿瘤的治疗方法。其 Paltusotine 是一种口服生长抑素受体 2 型 (SST2) 激动剂，目前正处于治疗肢端肥大症的 3 期临床开发阶段和治疗与神经内分泌肿瘤相关的类癌综合征的 2 期临床开发阶段。该公司已在 CRN04894 的 1 期临床研究中展示了药理学概念验证，CRN04894 是一种口服 ACTH 拮抗剂，目前正处于治疗先天性肾上腺增生和库欣病的 2 期临床研究阶段。其候选药物是口服的小分子新化学实体，是公司内部药物发现工作的结果，包括针对各种内分泌疾病（如甲状旁腺功能亢进症、多囊肾病、格雷夫斯病、甲状腺眼病、糖尿病和肥胖症）的其他项目。
公司简介
公司代码CRNX
公司名称Crinetics Pharmaceuticals Inc
上市日期Jul 18, 2018
CEODr. R. Scott Struthers, Ph.D.
员工数量437
证券类型Ordinary Share
年结日Jul 18
公司地址6055 Lusk Blvd.
城市SAN DIEGO
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编92121
电话18584506464
网址https://www.crinetics.com/
公司代码CRNX
上市日期Jul 18, 2018
CEODr. R. Scott Struthers, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Wendell Wierenga, Ph.D.
Dr. Wendell Wierenga, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
116.15K
+6.32%
Dr. Stephen F. Betz, Ph.D.
Dr. Stephen F. Betz, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
99.28K
-8.58%
Mr. Tobin C. (Toby) Schilke
Mr. Tobin C. (Toby) Schilke
Chief Financial Officer
Chief Financial Officer
52.00K
--
Ms. Caren Deardorf
Ms. Caren Deardorf
Independent Director
Independent Director
16.30K
+73.40%
Dr. Camille L. Bedrosian, M.D.
Dr. Camille L. Bedrosian, M.D.
Independent Director
Independent Director
16.30K
+73.40%
Dr. Weston A. Nichols, Ph.D.
Dr. Weston A. Nichols, Ph.D.
Independent Director
Independent Director
16.30K
+73.40%
Ms. Stephanie S. Okey
Ms. Stephanie S. Okey
Independent Director
Independent Director
16.30K
+73.40%
Dr. Dana Pizzuti, M.D.
Dr. Dana Pizzuti, M.D.
Chief Medical and Development Officer
Chief Medical and Development Officer
--
--
Ms. Isabel Kalofonos
Ms. Isabel Kalofonos
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Wendell Wierenga, Ph.D.
Dr. Wendell Wierenga, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
116.15K
+6.32%
Dr. Stephen F. Betz, Ph.D.
Dr. Stephen F. Betz, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
99.28K
-8.58%
Mr. Tobin C. (Toby) Schilke
Mr. Tobin C. (Toby) Schilke
Chief Financial Officer
Chief Financial Officer
52.00K
--
Ms. Caren Deardorf
Ms. Caren Deardorf
Independent Director
Independent Director
16.30K
+73.40%
Dr. Camille L. Bedrosian, M.D.
Dr. Camille L. Bedrosian, M.D.
Independent Director
Independent Director
16.30K
+73.40%
Dr. Weston A. Nichols, Ph.D.
Dr. Weston A. Nichols, Ph.D.
Independent Director
Independent Director
16.30K
+73.40%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
13.16%
The Vanguard Group, Inc.
9.92%
Wellington Management Company, LLP
7.36%
BlackRock Institutional Trust Company, N.A.
7.23%
Driehaus Capital Management, LLC
6.66%
Other
55.68%
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
13.16%
The Vanguard Group, Inc.
9.92%
Wellington Management Company, LLP
7.36%
BlackRock Institutional Trust Company, N.A.
7.23%
Driehaus Capital Management, LLC
6.66%
Other
55.68%
股东类型
持股股东
占比
Investment Advisor
52.41%
Investment Advisor/Hedge Fund
43.36%
Hedge Fund
10.51%
Venture Capital
2.08%
Individual Investor
2.02%
Research Firm
1.93%
Private Equity
1.07%
Pension Fund
0.47%
Bank and Trust
0.34%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
512
107.01M
114.23%
-5.91M
2025Q1
523
107.13M
114.60%
-8.74M
2024Q4
502
104.03M
112.03%
+3.16M
2024Q3
472
88.80M
110.94%
-9.89M
2024Q2
454
86.41M
109.20%
-10.36M
2024Q1
412
84.26M
107.74%
-4.10M
2023Q4
379
74.72M
112.09%
-6.67M
2023Q3
357
73.94M
113.29%
+8.54M
2023Q2
317
58.83M
107.87%
-6.38M
2023Q1
297
60.10M
112.09%
-2.85M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Fidelity Management & Research Company LLC
12.33M
13.16%
+4.36M
+54.75%
Mar 31, 2025
The Vanguard Group, Inc.
9.29M
9.92%
+219.75K
+2.42%
Mar 31, 2025
Wellington Management Company, LLP
6.89M
7.36%
-59.17K
-0.85%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.77M
7.23%
+100.35K
+1.50%
Mar 31, 2025
Driehaus Capital Management, LLC
6.24M
6.66%
+98.89K
+1.61%
Mar 31, 2025
T. Rowe Price Associates, Inc.
5.02M
5.36%
-312.17K
-5.85%
Mar 31, 2025
Farallon Capital Management, L.L.C.
4.61M
4.92%
+530.00K
+13.01%
Mar 31, 2025
EcoR1 Capital, LLC
4.29M
4.58%
--
--
Mar 31, 2025
Janus Henderson Investors
3.42M
3.66%
+629.00K
+22.50%
Mar 31, 2025
State Street Global Advisors (US)
3.28M
3.5%
+292.44K
+9.78%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Tema Neuroscience and Mental Health ETF
4.11%
Tema Heart & Health ETF
2.79%
ALPS Medical Breakthroughs ETF
1.82%
Virtus LifeSci Biotech Clinical Trials ETF
0.8%
First Trust Multi-Manager Small Cap Opportunities ETF
0.72%
SPDR S&P Biotech ETF
0.66%
BNY Mellon Innovators ETF
0.46%
Direxion Daily S&P Biotech Bull 3X Shares
0.38%
ProShares Ultra Nasdaq Biotechnology
0.3%
Invesco Nasdaq Biotechnology ETF
0.3%
查看更多
Tema Neuroscience and Mental Health ETF
占比4.11%
Tema Heart & Health ETF
占比2.79%
ALPS Medical Breakthroughs ETF
占比1.82%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.8%
First Trust Multi-Manager Small Cap Opportunities ETF
占比0.72%
SPDR S&P Biotech ETF
占比0.66%
BNY Mellon Innovators ETF
占比0.46%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.38%
ProShares Ultra Nasdaq Biotechnology
占比0.3%
Invesco Nasdaq Biotechnology ETF
占比0.3%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
